Goldman Sachs raised the firm’s price target on Incyte (INCY) to $90 from $80 and keeps a Neutral rating on the shares. After strong sector performance in 2025 driven by market dynamics, easing policy risks, and improving fundamentals, momentum is expected to continue in 2026 as these factors and their secondary effects, such as M&A, persist, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s INCB123667 Clears a Key Early Hurdle With Completed Phase 1 Study
- 3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026
- Palvella Therapeutics appoints Vimal Patel as SVP, medical affairs
- Balanced Risk-Reward for Incyte as Monjuvi’s Frontline DLBCL Win Offers Modest Upside in a Crowded Market
- Morning Movers: Incyte gains following frontMIND trial results